Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDORA trial of pembrolizumab plus platinum-etoposide in treatment-naive advanced Merkel cell carcinoma
2022-500988-12-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Oct 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, cisplatin, carboplatin and etoposide in Merkel cell carcinoma (MCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Planned start Oct 2023; status: authorised.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2022-500988-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500988-12-00.